Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EBIT: 2010-2024

Historic EBIT for Northwest Biotherapeutics (NWBO) over the last 15 years, with Dec 2024 value amounting to -$66.5 million.

  • Northwest Biotherapeutics' EBIT rose 3.25% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.9 million, marking a year-over-year decrease of 2.78%. This contributed to the annual value of -$66.5 million for FY2024, which is 19.82% down from last year.
  • According to the latest figures from FY2024, Northwest Biotherapeutics' EBIT is -$66.5 million, which was down 19.82% from -$55.5 million recorded in FY2023.
  • Over the past 5 years, Northwest Biotherapeutics' EBIT peaked at -$52.7 million during FY2021, and registered a low of -$86.6 million during FY2020.
  • For the 3-year period, Northwest Biotherapeutics' EBIT averaged around -$63.1 million, with its median value being -$66.5 million (2024).
  • Per our database at Business Quant, Northwest Biotherapeutics' EBIT plummeted by 209.54% in 2020 and then spiked by 39.15% in 2021.
  • Yearly analysis of 5 years shows Northwest Biotherapeutics' EBIT stood at -$86.6 million in 2020, then surged by 39.15% to -$52.7 million in 2021, then fell by 27.47% to -$67.2 million in 2022, then grew by 17.38% to -$55.5 million in 2023, then dropped by 19.82% to -$66.5 million in 2024.